8-K: Applied Therapeutics Receives Complete Response Letter from FDA for Govorestat in Classic Galactosemia Treatment

The FDA has issued a Complete Response Letter for Applied Therapeutics' New Drug Application for govorestat, citing deficiencies in the clinical application.

Summary

• Applied Therapeutics has received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for govorestat, a treatment for Classic Galactosemia.
• The FDA has determined that it cannot approve the NDA in its current form due to deficiencies in the clinical application.
• Applied Therapeutics plans to request a meeting with the FDA to discuss the requirements for a potential resubmission of the NDA or appeal the decision.
• The company acknowledges that the announcement contains forward-looking statements that involve risks and uncertainties.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the FDA's rejection of the NDA, which introduces uncertainty and delays. While the company is taking steps to address the issues, the overall outlook is unfavorable.

Positives

• Applied Therapeutics is actively engaging with the FDA to address the issues raised in the CRL.
• The company is exploring options for resubmission or appeal, indicating a commitment to bringing govorestat to market.

Negatives

• The FDA has rejected the NDA for govorestat in its current form.
• The CRL indicates significant deficiencies in the clinical application, requiring substantial work to address.
• There is uncertainty regarding the timeline and likelihood of future approval.

Risks

• The company faces the risk of not being able to resubmit the NDA successfully.
• There is a risk that the FDA may not approve the drug even after resubmission.
• The company's future revenue and capital requirements may be impacted by the delay in approval.
• The company's ability to maintain and establish collaborations or obtain additional funding may be affected.

Future Outlook

The company plans to engage with the FDA to determine the path forward for govorestat, including a potential resubmission or appeal. The timing and outcome of these actions are uncertain.

Management Comments

• The company is reviewing the feedback from the FDA and plans to immediately request a meeting to discuss requirements for a potential resubmission of the NDA or appeal of the decision along with appropriate next steps.

Industry Context

This announcement highlights the challenges and risks associated with drug development and regulatory approvals in the pharmaceutical industry. The rejection of an NDA is not uncommon and underscores the rigorous standards set by regulatory bodies like the FDA.

Comparison to Industry Standards

• The FDA's issuance of a Complete Response Letter is a standard regulatory action when an application does not meet the required criteria for approval.
• Other pharmaceutical companies have faced similar setbacks in the drug approval process, requiring additional clinical trials or data to address deficiencies.
• The process of resubmitting an NDA after a CRL is a common practice in the industry, although the success rate varies.

Stakeholder Impact

• Shareholders may experience a negative impact on the stock price due to the delay in drug approval.
• Patients with Classic Galactosemia may face a delay in accessing a potential new treatment option.

Next Steps

• Applied Therapeutics plans to request a meeting with the FDA to discuss the requirements for a potential resubmission of the NDA or appeal of the decision.

Key Dates

Keywords

FDA, Complete Response Letter, Govorestat, Classic Galactosemia, New Drug Application, Clinical Application, Aldose Reductase Inhibitor, CNS, Resubmission, Appeal